Allopurinol use in pregnancy in three women with inflammatory bowel disease: safety and outcomes: a case series

BMC Gastroenterology

Jane M Andrews²  Peter A Bampton⁵  Rupert W Leong¹  Matt P Doogue³  Muhammad W Fazal⁴ 

[1] Gastroenterology and Liver Services, Sydney Local Health District, Concord Hospital, Sydney, NSW 2139, Australia;IBD Service, Department of Gastroenterology & Hepatology and School of Medicine at Royal Adelaide Hospital, Adelaide, SA 5000, Australia;Endocrinology/Clinical Pharmacology, Flinders University School of Medicine and Flinders Medical Centre, Bedford Park, SA 5042, Australia;Internal Medicine Service, Royal Adelaide Hospital, Adelaide, SA 5000, Australia;Department of Gastroenterology and Hepatology, Flinders Medical Centre, Bedford Park, SA 5042, Australia

关键词: 6-mercaptopurine;    Azathioprine;    Ulcerative colitis;    Inflammatory bowel disease;    Teratogen;    Pregnancy;    Allopurinol;   

Others  :  856813
DOI  :  10.1186/1471-230X-13-172

 received in 2013-05-02, accepted in 2013-12-12,  发布年份 2013

【 摘 要 】

Background

Allopurinol is a frequently prescribed drug. In inflammatory bowel disease patients who shunt thiopurine metabolism towards more toxic and less desirable pathways, allopurinol is proving to be an effective add on therapy with good resultant disease control and less treatment side effects. As many such patients are young, the potential for pregnant women to be exposed to allopurinol is increasing. The safety of allopurinol in pregnancy is not known however.

Case presentation

We report three cases of safe use of allopurinol in pregnancy for women with inflammatory bowel disease. This included 2 patients with ulcerative colitis and 1 patient with fistulising Crohn’s disease. Allopurinol was used throughout pregnancy in all patients. All 3 pregnancies resulted in normal healthy babies born at term by Caesarean section.

Conclusion

It is important to evaluate and document the safety of allopurinol during pregnancy, as it is finding new roles in young patients. These three cases add significantly to the very limited data on allopurinol use in pregnancy. We encourage reporting of all cases of allopurinol use in pregnant patients and suggest an allopurinol pregnancy registry to document drug exposures and outcomes.

【 授权许可】

   
2013 Fazal et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Elion GB: The purine path to chemotherapy. Science 1989, 244:41-47.
• [2]Sparrow MP, Hande SA, Friedman S, Lim WC, Reddy SI, Cao D, Hanauer SB: Allopurinol safely and effectively optimizes thioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005, 22(5):441-446.
• [3]Sparrow MP: Use of allopurinol to optimize thiopurine immunomodulator efficacy in inflammatory bowel disease. Gastroenterol Hepatol (NY) 2008, 4(7):505-511.
• [4]Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA: 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002, 122(4):904.
• [5]Fujii T, Nishimura H: Comparison of teratogenic action of substances related to purine metabolism in mouse embryos. Jpn J Pharmacol 1972, 22(2):201-206.
• [6]Product information. Zyloprim. Burroughs Wellcome; 1990.
• [7]Hoeltzenbein M, Stieler K, Panse M, Wacker E, Schaefer C: Allopurinol use during pregnancy - outcome of 31 prospectively ascertained cases and a phenotype possibly indicative for teratogenicity. PLoS ONE 2013, 8(6):e66637.
• [8]Kozenko M, Grynspan D, Oluyomi-Obi T, Sitar D, Elliott AM, Chodirker BN: Potential teratogenic effects of allopurinol: a case report. Am J Med Genet 2011, 155A(9):2247-2252.
• [9]Seinen ML, de Boer NK, van Hoorn ME, van Bodegraven AA, Bouma G: Safe use of allopurinol and low-dose mercaptopurine therapy during pregnancy in an ulcerative colitis patient. Inflamm Bowel Dis 2013, 19(3):E37.
• [10]Awidi AS, Tarawneh MS, Shubair KS, Issa AA, Dajani YF: Acute leukemia in pregnancy: report of five cases treated with a combination which included a low dose of Adriamycin. Eur J Cancer Clin Oncol 1983, 19(7):881-884.
• [11]O’Donnell R, Costigan C, O’Connell LG: Two cases of acute leukaemia in pregnancy. Acta Haematol 1979, 61(5):298-300.
• [12]Boros SJ, Reynolds JW: Intrauterine growth retardation following third-trimester exposure to busulfan. Am J Obstet Gynecol 1977, 129(1):111-112.
• [13]Chocair P, Duley J, Simmonds HA, Cameron JS, Ianhez L, Arap S, Sabbaga E: Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen. Lancet 1993, 342:83-84.
• [14]Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB: Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007, 5(2):209-214.
• [15]Gearry RB, Day AS, Barclay ML, Leong RW, Sparrow MP: Azathioprine and Allopurinol: a two-edged interaction. J Gastroenterol Hepatol 2010, 25(4):653-655.
• [16]Cornish J, Tan E, Teare J, Teoh TG, Rai R, Clark SK, Tekkis PP: A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 2007, 56(6):830-837.
• [17]Mahadevan U, Sandborn WJ, Li DK, Hakimian S, Kane S, Corley DA: Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 2007, 133(4):1106-1112.
• [18]Hanan IM, Kirsner JB: Inflammatory bowel disease in the pregnant woman. Clin Perinatol 1985, 12(3):669-682.
• [19]Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS: Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis 2013, 19(1):15-22.
• [20]Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH: The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003, 124(1):9-17.
• [21]Alstead EM, Ritchie JK, Lennard-Jones JE, Farthing MJ, Clark ML: Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990, 99(2):443-446.
• [22]Jharap B, de Boer NK, Stokkers P, Hommes DW, Oldenburg B, Dijkstra G, van der Woude CJ, de Jong DJ, Mulder CJ, van Elburg RM, van Bodegraven AA: Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut 2013. Published Online First: February 19. doi:10.1136/gutjnl-2012-303615